About Beacon Biosignals
Beacon Biosignals is a private company based in Boston, Massachusetts. It has reported $133,180,730 raised in three offerings on Form D since February 2019. Its chief executive is Pavel Raifeld.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | Apr 15, 2026 | $103,280,711fully sold | 43 | $2.4M | EquityRule 506(b) | Form D ↗ |
| Sep 17, 2021 | Oct 4, 2021 | $29,850,019fully sold | 42 | $710K | EquityRule 506(b) | Form D ↗ |
| Jan 24, 2019 | Feb 7, 2019 | $50,000of $1.6M target | 1 | $50,000 | OptionsRule 506(b) | Form D ↗ |
| Total, three offerings | $133,180,730 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Beacon Biosignals's Form D filed Apr 15, 2026.
CD
Caitlin Donovan
Partner, General Catalyst and director
PR
Pavel Raifeld
CEO Innoviva and director
JD
Jacob Donoghue, M.D., Ph.D.
CEO and Co-founder, director
NR
Earlier filings also listed Jacob Donoghue (president & chief executive officer, director, last listed Oct 2021).
Sources
- SECBeacon Biosignals, Inc. filing history
- CompanyTerms of Service
- CompanyAbout Us
- CompanySnap Diagnostics acquisition